We help people with diabetes keep their feet by screening for and diagnosing peripheral artery disease (PAD) early so it can be treated before amputation becomes necessary.
Current Status
Prototypes developed at Columbia University were successfully tested on 150 human subjects. The VOTIS prototype has been tested on subjects and is about to be used in a multi-site feasibility trial at Hadassah Hospital in Jerusalem and at Columbia University Irving Medical Center. We hope to launch the device commercially at the end of 2022.
Problem or Opportunity
Globally, more than 200 million people are estimated to suffer from PAD. If someone with PAD were to get a cut, a wound, or even an abrasion in the foot, lack of blood flow and/or oxygen in the blood may prevent or slow wound healing. This may cause a diabetic foot ulcer to form. Diabetic foot ulcers (DFUs) develop in up to 1/3 of people with diabetes, and over half of DFUs will develop an infection. Of these, 17% will require an amputation. There is no easy and accurate way to test for PAD, especially in people with diabetes.
Solution (product or service)
Using Hemodynamic Optical Vascular Response ("HOVR") technology licensed from Columbia University, VOTIS has developed the PedCheck device to screen for and diagnose PAD even when it is asymptomatic. This enables doctors to assess disease progression and the impact of treatment. The PedCheck is easy to administer (in a 5-minute test), non-invasive, and cloud-based for AI/machine learning analysis.
Business model
B2B. The devices are inexpensive to make and will be leased to healthcare providers at a low price Tests will be billed on a SaaS basis including use of consumables.
